DaVita Inc. (DVA) Earnings Call Transcript & Summary

February 13, 2025

New York Stock Exchange US Health Care Health Care Providers and Services earnings 55 min

Earnings Call Speaker Segments

Nic Eliason

executive
#1

Thanks for joining us on this call for the fourth quarter. My name is Nic Eliason, and I serve as Group Vice President of Investor Relations. With me are our CEO, Javier Rodriguez, and our CFO, Joel Ackerman. I want to point out that we might present forward-looking statements on this call as defined under the federal securities laws. Known and unknown risks and uncertainties apply to all such statements, and those factors could lead to actual results differing materially from what the forward-looking statements describe. To learn more about these risks and uncertainties, please look at the press release for our fourth quarter earnings along with our SEC filings, which include our latest annual report on Form 10-K, every later quarterly report on Form 10-Q, and any other documents we subsequently file with the SEC. The information we currently have forms the basis for our forward-looking statements, and we have no intention of, nor do we assume any obligation to, revise those statements, unless the law demands it. We also want to note that certain non-GAAP financial measures will be covered on this call. You can find a reconciliation of those non-GAAP measures against the closest comparable GAAP financial measures in the earnings press release we furnished to the SEC, which is also posted on our website. At this point, I'll hand the call over to Javier Rodriguez.

Javier Rodriguez

executive
#2

Thanks, Nic, and I appreciate everyone being on today's call. As 2025 gets underway, we're marking DaVita's 25th anniversary. Over those years, our attention has stayed on better clinical results, improving life quality for patients and care teams alike, and acting as a driver of positive transformation for the health care system. It's a privilege to continue that legacy, and we're eager to keep expanding these boundaries during 2025 and beyond. Today I'll walk through key points from our 2024 results, share updates on a few pieces of our growth path, and wrap up with 2025 guidance. Before that, though, I'll start where we always do, with a clinical achievement. As I mentioned, we're marking 25 years, a stretch that includes extraordinary clinical strides. Alongside our physician partners, we've accomplished a great deal for those who have placed their trust in us for their care. Among the numerous achievements, we've pushed hard to greatly broaden patient access to care, particularly for those in the country's more rural communities. We went past in-center treatment and backed the growth of home dialysis, with over 4 out of every 5 patients residing within 10 miles of a DaVita home program. Of those patients currently receiving treatment at home, over 80% rely on connected cyclers, a technology allowing our care teams to monitor remotely and boost patient health outcomes. We've grown from a dialysis provider into a comprehensive kidney care company, tackling every stage of the Kidney Care journey. That covers our Kidney Smart program, through which we've delivered free education about managing chronic kidney disease to over 300,000 individuals, and Integrated Kidney Care, or IKC, where we've led the way in value-based care delivery, partnering effectively with health plans and CMS to deliver holistic patient care while confronting the health care system's rising costs. Lastly, we've elevated care quality in 13 countries outside the United States, where we've consistently surpassed clinical benchmarks in every market. I'm energized by the strides we've taken to generate better outcomes and improve millions of lives. And naturally, there's plenty left to do. As we look toward the next chapter, our vision is to sustain our steadfast pursuit of a healthier tomorrow. Turning to 2024 performance. We closed the year strongly, generating full year adjusted operating income and adjusted EPS in the top half of our guidance range, with year-over-year growth of 21% and 26%, respectively; during a year that brought several unusual obstacles, among them the Change Healthcare outage and hurricane-related disruption to our supply chain, I'm reminded of how resilient our organization is and moved by the dedication of our committed care teams. In U.S. dialysis, we keep gaining from innovation in our revenue cycle operations. Stronger collection performance and contracting drove higher revenue per treatment growth, compensating for a slower-than-expected rebound in treatment volume. Even though we saw positive volume growth for the first time in a year since the pandemic began, full-year growth came in under what we had anticipated. In Q4, mortality and mistreatment rates stayed high, and new patient starts took a hit because of supply constraints on our peritoneal dialysis solutions. On the cost side, we keep up our history of finding efficiencies and carrying out cost-saving programs. Outside of U.S. dialysis, we grew our international footprint and kept expanding IKC. Of the 4 Latin America acquisitions announced last year, we have now closed 3, with Brazil anticipated to close in midyear 2025. Through IKC, we keep advancing on our path of providing sustainable integrated care. For 2024, IKC results matched our expectations, with an adjusted operating loss of $35 million. Our strategy is still centered on bettering health outcomes and quality of life for patients, reducing avoidable medical expense, keeping tight control over G&A costs, and chasing the right opportunities to reach scale. As a reminder, during last quarter we called attention to the temporary shutdown of Baxter's North Cove facility caused by Hurricane Helene and the resulting effect on home dialysis. Because of these difficulties, we took on roughly $6 million of operating income impact in Q4, driven by pricier saline, fewer patient starts stemming from PD solution availability, and reduced productivity among our home caregivers. That negative impact ended up smaller than we had initially anticipated, thanks to the remarkable work of our supply and physician partners, as well as our procurement and operating teams. By the end of 2024, we had gone back to admitting new home patients at rates consistent with history. Still, our inability to put new patients on PD played a part in lower new admits during Q4, which will drag down volume growth in 2025. This is baked into our estimate of roughly $30 million of negative impact to adjusted operating income in 2025. Turning now to orals in the bundle. Starting January 1 of this year, oral drugs moved from the Medicare drug benefit into the dialysis benefit; this policy is plainly a positive for dialysis patients. We're eager to broaden patient access and widen options for prescribers. We estimate that as much as 20% of patients lacked coverage and can now get this therapy. Our patients will receive support from dieticians and have access to every major class of phosphate binders, covering both branded and generic choices. We project the 2025 OI contribution will land between $0 and $50 million; with our 2025 guidance, we're once again on a more typical adjusted OI growth trajectory. Looking at our 2025 guidance, the midpoint for adjusted OI growth sits at 5.2%, while adjusted EPS growth comes in at 11%, and you can find the specific ranges laid out in our press release. This follows a robust 2023 and 2024, two years where we surpassed the upper limit of the guidance ranges we initially set, even with soft volume growth, by generating momentum in other areas of our core and ancillary operations. A key priority for 2025 will, naturally, remain a sharp emphasis on volume, since we anticipate an eventual comeback to a 2% growth trend, though we acknowledge that predicting the timing is challenging. Even with that uncertainty, we stay confident about achieving adjusted OI growth within our target range of 3% to 7% in the years to come. We'll keep putting money into distinctive capabilities that fuel results throughout our platform, while returning surplus capital to shareholders via share repurchases; our dedication to the capital allocation strategy endures as the path to reaching double-digit growth in earnings per share. At this point, I'll hand things over to Joel, who will walk through our financial performance and outlook in greater depth.

Joel Ackerman

executive
#3

Thanks, Javier. Adjusted operating income for the fourth quarter came to $491 million, which lifted adjusted OI for the whole of 2024 to $1.98 billion. Adjusted EPS in Q4 reached $2.24, bringing the full year adjusted EPS figure to $9.68. Free cash flow totaled $281 million during the fourth quarter, and $1.16 billion across the full year. I'll begin today by covering some specifics from the fourth quarter, then move into details around our 2025 guidance. U.S. treatment volume for the fourth quarter rose 30 basis points compared with the fourth quarter of 2023, even as treatments per day fell 80 basis points against that same quarter of 2023. In the fourth quarter, treatment volume came in below what we had expected, and there were two reasons for that. First, we saw more missed treatments than we had planned for, largely because severe weather events caused a 40 basis point hit to year-over-year growth in the quarter. Second, new-to-dialysis admissions were lower than our forecast, due in part to Hurricane Helene's effect on PD supply. We figure the PD supply issue resulted in about 350 lost admissions during the quarter. For the entire year, treatment growth came to 47 basis points, which was slightly below the low end of the guidance we gave last quarter. Revenue per treatment climbed roughly $1 from one quarter to the next in Q4, driven mostly by seasonality, and that pushed full year RPT growth to 3.7% compared with 2023. On the patient care side, each treatment cost $7 more than the prior quarter. Seasonality was the primary reason — health benefits and other field costs played a role — and sequentially higher center closure costs added further pressure. Quarter-over-quarter, G&A expenses increased by $15 million. Given that our fourth quarter normally carries heavier G&A spending, this was in line with what we anticipated. Compared with the third quarter, depreciation and amortization were down $14 million. Reduced center closure costs accounted for most of that decline. Adjusted international OI was $17 million lower than in the third quarter. The reason was a $19 million reserve taken against aged accounts receivable in Brazil. Apart from that, operations in our international business are performing as expected. Earlier in the quarter, we completed the third acquisition we made in Latin America during 2024, which broadened our footprint in Colombia. As for Brazil, that expansion is still being reviewed by the government, and we anticipate completing it around the middle of the year. Our value-based care segment, Integrated Kidney Care, finished 2024 with an adjusted operating loss of $35 million for the entire year. We keep carrying out our long-term plan. Although results for the full year beat what we had projected for 2024 by roughly $15 million, that is mostly attributable to the timing of revenue tied to our value-based care contracts along with ordinary fluctuations. Turning to the OI line, debt expense in the fourth quarter was about level with the third quarter. At year's close, our leverage ratio stood at slightly above 3x EBITDA. During Q4, we bought back 2.3 million shares, and roughly 800,000 more have been repurchased since 2025 began. Now I'll move on to what we expect for 2025. For adjusted operating income, our 2025 guidance spans $2.01 billion to $2.16 billion. Looking at the midpoint, that represents 5.2% growth versus the prior year. Let me walk through a few details, starting with treatment volume. Built into the midpoint of our adjusted OI guidance range is flat growth in treatment volume for 2025 compared with 2024. When it comes to the main underlying drivers of treatment volume — that is, admissions, mortality, and mistreatment rate — what our guidance assumes is that the trends from 2023 and 2024 stay broadly the same, with nothing significant changing. Built into this forecast are roughly 50 basis points of headwinds that are specific to 2025, tied to the count of treatment days, plus the headwind tied to the PD admissions disruption in Q4. Turning to revenue per treatment, we're looking at 4.5% to 5.5% growth in revenue per treatment versus a year earlier. Roughly 40% of that expected growth comes from new oral phosphate binder reimbursement. The other 60% comes from rate increases, collections improvements, and changes in mix. On the patient care cost per treatment side, our forecast is for an increase of 6% to 7% over the prior year. Oral phosphate binders remain a key factor here, accounting for roughly 40% of that anticipated growth versus last year. The remaining 60% of the growth, as we see it, stems from labor inflation and other cost pressures, partially counterbalanced by lower center closure costs than we had in 2024. For U.S. dialysis G&A, we're looking at an increase of approximately 4%, driven by what we're investing in our teams, capabilities, and processes, with a reduction in center closure costs relative to 2024 offsetting some of that. U.S. Regarding depreciation and amortization tied to dialysis, our projection is a decrease of about $25 million to $30 million. The reasons are reduced expenses from shutting down centers and smaller CapEx amounts over the past few years. Turning to IKC, we foresee adjusted operating income staying fairly level against the prior year when compared with 2024. This matches our earlier outlook, except that between $10 million and $15 million in value-based care revenue has shifted from 2025 into 2024. For international, we're looking at adjusted OI growth of around $50 million versus the previous year. That number captures a few things coming together: the deals we closed in Latin America during 2024, the allowance we set up against older receivables in Brazil that weighed on last year's results, and ongoing expansion in the markets where we already operate. Turning to earnings per share: for 2025, our adjusted EPS outlook sits between $10.20 and $11.30. At the middle of that guidance, adjusted EPS would climb 11% versus 2024, with the main drivers being growth in adjusted operating income and fewer shares outstanding thanks to buybacks, partly offset by the entire annualized cost of higher interest on our debt. Below the operating income line, we expect other losses of about $75 million, which is more or less unchanged from 2024. On interest expense, our projection is between $525 million and $555 million, and that works out to roughly $135 million each quarter. For an adjusted effective income tax rate, we're looking at 24% to 26%, which matches what we saw in 2024. When it comes to free cash flow, the guidance for 2025 sits at $1 billion to $1.25 billion. Our approach to capital allocation hasn't changed from previous years. We'll be targeting growth opportunities that use capital efficiently, with leverage aimed at 3 to 3.5x EBITDA, and anything beyond that goes back to shareholders via share repurchases. That's everything I had prepared for today. Operator, please open the line for questions.

Joanna Gajuk

analyst
#4

I suppose I'll start with the outlook for volume in '25. You mentioned flat at the midpoint. Does a range come along with your OI range?

Joel Ackerman

executive
#5

Joanna, Joel speaking. I appreciate the question. Yes, volume definitely has a range tied to it. There's quite a bit of natural variability across all 3 inputs — admissions, mortality and mistreatment rate — and that would be among the factors that would drive the range we provided for OI.

Joanna Gajuk

analyst
#6

Could you provide something like a spread — maybe minus 1 to plus 1, or even tighter than that? Or what's the proper way for us to frame it? What possible outcomes are we looking at here?

Joel Ackerman

executive
#7

Right. This year we chose not to put a number on it, and instead to center on the middle point of the range. I'm not sure the swings we'd observe would be all that different from the swings we would have contemplated as we entered last year, but our forecast made at the start of 2024 came in slightly under; so we were somewhat reluctant to offer a range at this point.

Joanna Gajuk

analyst
#8

Regarding that comparable figure — the volumes came in more or less level during '24, correct? I just want to confirm that; so essentially you're expecting a comparable pattern across all of '25?

Joel Ackerman

executive
#9

The comparable figure for '24 came to about 50 basis points higher. To be precise, it's 47 basis points. And let me make this clear for everybody — whenever we provide a volume forecast, what we're projecting is treatment volumes; we do provide various volume metrics, such as NAG and others, that you're able to work out on your own, but our actual projection concerns total treatment volumes; thus the '24 figure rose 50 basis points. For '25, the midpoint of that range sits flat. Essentially 2 factors are producing this decrease. The first involves treatment days. Keep in mind that 2024 included a leap year, which contributed roughly 20 basis points of additional growth during '24 that simply won't occur in '25; and second, we discussed how the hurricane disrupted PD supply; what that meant was that during Q4, for a stretch of time, we couldn't bring in new peritoneal dialysis patients. A portion of those patients ended up receiving care in center, yet our estimate is that we lost approximately 350 patients who would have otherwise chosen DaVita, and who we believe opted to get peritoneal dialysis through a different provider. Since those 350 patients were lost during Q4, the effect on Q4 volume was minimal. The effect on 2025 volume will be considerably larger, amounting to somewhere around 15 to 20 basis points of growth across 2025. So once you combine that with the days, that essentially explains the 50 basis point drop. As for the core metrics — mistreatment rate, mortality, and admissions — our guide treats those as being approximately in line with what we observed during '24.

Joanna Gajuk

analyst
#10

Okay, thanks. And if I could follow up on that figure, when you gave the range of 0 to 50 for the OI benefit tied to adding the oral drugs into the bundle — I have to say I'm somewhat taken aback that it actually starts at 0. Could you share a bit more detail on why the range is that broad, and also what situation would make it a done deal, so to speak?

Javier Rodriguez

executive
#11

Joanna, it's Javier here. I'll take that question, and for anyone who hasn't been following the orals in the bundle — this drug class is led by phosphate binders, a medicine that lowers how much dietary phosphate gets absorbed. It sat in part D and is shifting into Part B as in boy, and there are 3 things to weigh. First is mix — which phosphate binder, since some are generic and some are branded. Second is volume. And third is adherence; the pill burden here is heavy. You need to take it with meals and snacks, and so on. As a result, lots of people, for various reasons, have low adherence. So this is quite new for us. Given those 3 factors, I believe we're being prudent by handing you a wide range; and after we gain some experience, we'll find out how it shakes out. But the middle of that range strikes us as the most probable point based on what we're seeing today. Then let me add 1 final note regarding volume, which is that it's tough to observe volume so far because frequently, patients collect prescriptions covering 90 days. And given that we're only in February now, if you got your prescription in December, or November, you may not — we lack visibility into which medication you're taking; that's the reason the range looks so wide at this moment.

Albert Rice

analyst
#12

If I understood correctly, you mentioned that costs for treating patients would rise roughly 6% to 7%, mostly because of adding the phosphate binder. Could you address that separately? Has anything shifted — any notable shift in how you view growth in patient treatment costs compared with what you observed in '24?

Joel Ackerman

executive
#13

Absolutely. Here's how I'd frame it — their range sits near this, but I'll take the midpoints. For patient care cost growth, the midpoint would be 6.5%; of that, 3.75% comes from our historical costs, and 2.75% comes from putting the orals into the bundle. So when you stack it against prior years, 3.75% is the figure to use. Breaking it further, we usually split it into labor and everything else, and for next year we expect both to grow at roughly the same rate. Labor, we continue to expect somewhat more pressure than existed before COVID, while everything else also rises around that same 3.75% range.

Albert Rice

analyst
#14

All right. Then perhaps one more question, following up; regarding what you said about deploying capital, can you give us a number for your expected share buyback activity? Do you have any thoughts on the transaction pipeline, whether abroad or here at home, and what conditions look like out there?

Joel Ackerman

executive
#15

As for buybacks. I'll stay consistent with prior remarks, meaning our approach is unchanged. We'll seek growth that makes efficient use of capital, whether by putting money into the business or via M&A, and we'll maintain our leverage — or aim for leverage — between 3 and 3.5, where it stands at present, and any remaining funds will be directed to repurchasing shares. So no figure will be provided, though I wouldn't anticipate anything other than what has occurred before. Regarding M&A, a few opportunities are under review. And a scenario where we put hundreds of millions of dollars to work is definitely something I could envision. Yet, as I've noted before, I doubt we'll pursue anything — nothing currently visible ahead would, I believe, meaningfully alter the repurchase program.

Pito Chickering

analyst
#16

The U.S. RD figures indicate roughly unchanged incidence for renal disease during '24, and your treatment numbers have stayed fairly level this year as well. Right now there's certainly a sizable debate regarding how much SGLT2 inhibitors are affecting treatment volumes. Could you help put numbers to the new starts that you observed in 2024 compared with 2023? This would just help the payer side compare what DaVita is experiencing against what the U.S. RD data is telling us.

Javier Rodriguez

executive
#17

Let me take part of that question, and then Joe can provide the specific answer you're after, because several people have come to us assuming these medications are having an effect; and the truth is that our physicians have examined this very closely; and the chances that this is affecting our patient population are fairly low at this point; and let me explain why. First, the information we have from CMS puts the prevalence of CKD patients, advanced CKD, in the low teens. And adherence sits in the mid-60s. And so the likelihood of having an effect is low. If there were an effect, you would also observe the offset in mortality. So the math would hopefully be a positive, meaning it's extending people's longevity; and so when we speak with our medical professionals and they're going through all this data, they are quite confident that, that is unlikely to be the effect; now the second part of your question is a bit more specific, Joel?

Joel Ackerman

executive
#18

Yeah, so when it comes to the data, Pito, the growth we're seeing in admissions has actually been outpacing what the USRDS numbers show. It came in stronger during the early months of the year, then it dropped off quite a bit in Q4. Our growth in new-to-dialysis admissions was basically flat in Q4, and that's the first quarter it hasn't come in positive since — I believe, 8 quarters. So we've taken a close look at this. I'd make 2 points here. First, when you examine USRDS year-over-year, either new to dialysis or incidence growth, and we went through 10 years carefully right up to COVID. There was a great deal of noise in the numbers throughout COVID. But looking at the 10 years prior to COVID, the data is noisy. In 2 of those 10 years, incidence growth came in negative. Those years didn't point to any kind of secular trend — the data rebounded. It would swing back and forth, and it could rise as much as 3% year-over-year. And I believe there was a 6% total swing across that 10-year stretch. So we don't view negative — 1 year of negative data in USRDS as necessarily the beginning of a trend. And that view is grounded in history; so that's point one. Second, to build on what Javier said, if there is a negative admit impact hitting the industry right now, we believe the far more probable cause is mortality among CKD 4 patients stemming from COVID, rather than anything tied to SGLT2 inhibitors or GLP-1s, for the reason Javier gave. So again, 2 points. One, a negative year of incidence growth isn't something new. We've seen it previously; it hasn't automatically marked the start of a trend; and second, if there truly is a signal within that noise, we think it's far more likely to come from COVID than from these new drugs.

Pito Chickering

analyst
#19

All right. Then moving to PD, I suppose, at what point did your PD supplies settle down again after Baxter? And after that, could you kind of put a figure on how those new starts are now getting back toward typical levels? I get the leap year effect, and I get the number you gave for the drag of roughly 15, 20 basis points from those 350 patients we lost. But could you truly put a number on how new starts are returning to usual levels given that PD supplies are now back to normal?

Javier Rodriguez

executive
#20

Yes. So we are up and running again, back to where we should be. And as a result, you ought to see that figure rise once more. Before the hurricane, our mix sat in the mid-15s, just underneath that, roughly 15.4. So at present we're near 14.9; so we ought to see that come back into line, it will require some time, perhaps a year or so as the year unfolds. But we are back to normal.

Joel Ackerman

executive
#21

Let me clear up a couple of points for you, Pito. Things have returned to their usual state, yet the 350 admissions we forfeited are gone for the entirety of '25. They won't be returning to us, which explains the effect despite the fact that our admission rate is back to a typical level. Also, a second reminder for everybody: although PD patients receive treatment daily, our reported volumes are adjusted into in-center equivalents. As a result, our volume tally neither gains nor sheds numbers when someone switches between PD and in-center, or the other way around.

Pito Chickering

analyst
#22

Let me try posing this in yet another manner. During a stretch of 60 days, Baxter was unable to provide these PD supplies. I understand you lost those 350 patients, but with things back to normal now, what explains the range's midpoint staying flat? Why isn't that midpoint something like 50 or 100 basis points, after subtracting 20 bps for leap year and 20 bps for PD — why is it flat, at the new level, if patient trends had normalized by now?

Javier Rodriguez

executive
#23

Since those patients remain in center, they'll simply change modality, yet the treatments stay the same.

Joel Ackerman

executive
#24

Right. I'd view it as the identical 50 basis point effect that occurred in the prior year, stemming from mortality, admissions, and the mistreatment rate. After that, you need to deduct for these 2 factors that pertain only to 2025, and did not apply during 2024.

Justin Lake

analyst
#25

To start with, the noncontrolling interest appears somewhat larger than I would have anticipated based on the OI this quarter. Is there something I'm overlooking? What exactly is driving that figure? And did it come in above what you had forecast?

Joel Ackerman

executive
#26

Yeah. I appreciate that, Justin. It came in a bit higher than we had anticipated. I believe the correct approach for modeling MCI is as a percentage of U.S. dialysis operating income across the year; and my view is that nothing has shifted in that regard on the whole. There were certain collection dynamics tied to Change Healthcare that shifted items from 1 quarter into the next. That said, on the whole, I wouldn't point to any fundamental trend there.

Justin Lake

analyst
#27

So what you're telling me is that operating earnings' share isn't going up? It could be swapping back and forth from one quarter to the next, yet on the whole, the '25 ought to match the '24?

Joel Ackerman

executive
#28

Precisely.

Justin Lake

analyst
#29

All right, and the — my hope was that you might — I mean, you went through the majority of those below-the-line figures; even so, EPS appears somewhat weak compared to my expectation. The sole possibility that comes to mind is the number of shares. Would you care to walk through that — could you provide some sense of what you anticipate for share count?

Joel Ackerman

executive
#30

I would prefer not to. Let me try to consider what could be missing from that. It hinges on the way you're building your model. Should you be building it by business segment, my guess is the corporate segment will likely be $25 million worse in '25 than in '24. That is essentially tied to the timing of certain equity compensation. Beyond that, I believe if you're — we provided the other income, we provided the interest expense, we provided the tax rate. So I suspect share count is ultimately going to be the open question; and look, that's going to hinge on a number of factors, how much capital we put toward repurchasing shares, clearly, what the price of the stock is. It also gets affected by the timing of our share purchases throughout the year, since it's a weighted average count across the year. Perhaps we can discuss it separately, Justin. We can verify whether some arithmetic discrepancy exists.

Justin Lake

analyst
#31

Thanks for that. My next question concerns the revenue we generate for each treatment. There were a few points you raised. First, you indicated there's still some room to gain from collections, though when I heard you speak three months ago, my takeaway was that you believed this was fading away. So I'm wondering what level of gain you're anticipating there. You brought up payer mix as well. It would help to understand roughly where you finished the year and what you're projecting for the coming year. And since we're on payer mix, could you share perhaps what share of treatments originate from the exchanges? Or people covered through exchange plans?

Joel Ackerman

executive
#32

Certainly. Let me begin with collections. What you're observing here, I believe, reflects what we flagged throughout 2024 — namely, the full-year effect of collection gains that largely arrived around the midpoint of 2024, and that figure is roughly $50 million, approximately. Regarding mix, there's honestly nothing noteworthy to mention on MA mix; we'll follow the broader industry. Not much to report there. As for commercial mix, we currently sit near 11%, and we expect to add a few tens of basis points to that. When it comes to the exchanges, roughly 3% of the people we serve are enrolled in the exchanges at present.

Justin Lake

analyst
#33

And what did that figure look like before COVID, Joel, for exchanges?

Joel Ackerman

executive
#34

If we rewind to the pre-COVID period — I'll share with you the figure from prior to when the enhanced premium tax credits took effect, and it stood at approximately 2%.

Andrew Mok

analyst
#35

I appreciate you noting that phosphate binders account for 40% of the increase in revenue per treatment; based on that, it seems to come to roughly $25 per treatment for Medicare patients. Is that calculation correct? If it is, that appears somewhat low compared with the ASP figure CMS laid out in the final rate. So I'm just attempting to pin down the actual dollar amounts for Medicare patients in particular.

Joel Ackerman

executive
#36

No, Andrew, for a Medicare patient the figure is closer to $10 to $15. Just to walk everybody through how the numbers work: take the midpoint of that range, and keep in mind that orals through the bundle aren't something every one of our patients qualifies for. If you're covered commercially or through managed Medicaid, those are payer classes that don't receive this. And among the Medicare and Medicare Advantage patients who do, not all of them actually take it. That's the reason our figure of 40%, roughly $7.80 on our RPT, sits below the $10 to $15 — it simply isn't relevant to the full patient population.

Andrew Mok

analyst
#37

Understood. All right. Then regarding G&A per treatment, I believe it rose 6% quarter over quarter and 11% compared with the same period last year. That appears to be a significant step-up and possibly more pronounced than the usual seasonal pattern. Is there anything more you can share about what is causing that?

Javier Rodriguez

executive
#38

Yes. Thank you, Andrew. In my view, the optimal approach to G&A is to break it into 2 components. First is the — let's refer to it as the conventional piece, meaning viewing it as a cost base. The other piece is what now amounts to an investment portfolio sitting within it. So instances that spring to mind include IT, where we are realizing considerable gains on a separate expense line, or revenue operations, where you are capturing the upside, clearly, through RPT. Consequently, the preferable way to frame it is that this split is roughly half and half. As a result, you are simply absorbing the inflationary portion of the cost item, while we are achieving solid productivity from the remaining half.

Andrew Mok

analyst
#39

Understood. Alright. Then regarding the expenses for patient care, my understanding is that a settlement gain provided a boost during the quarter. Could you put a number on that for us?

Joel Ackerman

executive
#40

Just a moment. Yes, that isn't a figure I'm going to highlight. It's nothing significant, and it's fairly ordinary and minor.

Ryan Langston

analyst
#41

Thanks for all those details on guidance. Joel, I'm hoping I didn't overlook this, but could you address seasonality, perhaps on a consolidated basis for IKC? For instance, anything that differs from what we've seen historically, or any patterns we ought to keep in mind—maybe even how things split between the first and second halves?

Joel Ackerman

executive
#42

Sure. This is how I'd frame it. When it comes to operating income, 3 items stand out. To start, revenue per treatment is consistently softer in Q1 and then rises as the year goes on. As a result, there's usually a seasonality impact of about $5 on RPT during Q1 stemming from bad debt tied to patient pay; after that, RPT generally climbs throughout the year. That's item one. The second is IKC, which consistently leans toward the back half. Predicting IKC's seasonality is quite difficult, though I believe you can depend on it skewing to the back half in the Q3, Q4, and the dynamic can at times get complicated. And fourth, expenses usually rise in Q4, which can affect both patient care costs and G&A. Taking all of that together, I'd estimate our Q1 OI at approximately 20% of full year OI, expanding through Q2 and Q3, and occasionally dipping somewhat in Q4; that's on the OI line. When modeling EPS, you also need to factor in that share buybacks build up as the year moves along. Consequently, share count generally declines. That means you'll observe somewhat greater EPS growth as the year unfolds. So Q1 EPS is usually even below the 20% figure I mentioned for OI.

Ryan Langston

analyst
#43

Understood, and there's one additional item. Is there any way you could share where things stood at the beginning of the year, or where they'll stand as we begin it — something like an IKC figure comparing the SNP patient count with the other IKC lines? Then, any perspective on whether anything has shifted regarding the possibility of reaching breakeven in that business by 2026?

Javier Rodriguez

executive
#44

Yes. I appreciate the question. Our view is that the business will be roughly flat during this year, and there was a timing item we flagged, roughly $10 million, which moved into 2024. As a result, the OI line should appear fairly comparable in 2025. What I'd add is that we remain committed to that breakeven during the 2026 timeframe, and we issued that guidance back around 2021. We've stayed quite closely aligned with our model, so expectations haven't changed.

Joel Ackerman

executive
#45

Yeah. As for the SNP matter, I wouldn't really point to much of a shift in '25 compared with 2024.

Joanna Gajuk

analyst
#46

I've already gone through the majority of my questions, and the final item I have concerns your free cash flow guidance, which suggests that free cash flow might decline compared with the prior year. Is that simply due to 2024 having been so much stronger, or is there something worth mentioning?

Joel Ackerman

executive
#47

Yeah, I'd say the main factor worth mentioning is really movements in working capital. You can see significant fluctuations as each year comes to a close, and that's the reason our guidance spans such a broad range. When it comes to free cash flow, there isn't anything specific that I would point to.

Joanna Gajuk

analyst
#48

All right, and when it comes to shutting clinics, could you share some kind of range for what you've built into your '25 guidance regarding closures?

Javier Rodriguez

executive
#49

My sense is we've reached a fairly typical state at this point, so we'll shut down — how should I put it — what we did before the pandemic, which is roughly around 20 centers each year.

Pito Chickering

analyst
#50

To build on what Ryan asked regarding IKC — it appears that compared with the prior quarter, you added 900 patients in risk-based integrated care, yet you dropped 2,300 patients across the integrated care arrangements. So I suppose my question is, what caused the loss of those patients? Then the other piece is, as you noted, IKC tends to be weighted toward the back half of the year because of true-ups from managed care; and as your experience grows, when do you shift away from something closer to a cash-based accounting approach and toward an accrual approach, simply because you've gained more experience?

Joel Ackerman

executive
#51

My Chief Accounting Officer is seated opposite me at the table, giving me a stern look over cash accounting. Let me be clear about that. Cash accounting is not what we use. We're disciplined regarding the timing of revenue recognition and the arrival of information. With that said, Pito, I grasp what you're getting at; and yes, we've changed over time. Within our value-based care segment — the work we perform with MA — we've grown more at ease projecting revenue somewhat sooner. So on CKCC, the Medicare fee-for-service program, we've advanced on that front. We continue to take a more conservative stance and hold off until additional data arrives, until we've built stronger experience with it; and as for when that might shift, I believe that has yet to be determined. Regarding the member count, I'd caution against reading too much into it. Those figures will move as attribution shifts, and minor fluctuations such as these don't signal any fundamental shift within our IKC business.

Pito Chickering

analyst
#52

All right. My apologies go out to your Chief Accounting Officer regarding that matter. Now, when I consider 2025, how are the lives trending during this year? Should we expect yet another increase similar to what we've witnessed over the past several years? Or does this represent more of the steady pace you folks will maintain inside IKC?

Joel Ackerman

executive
#53

For 2025, I'd say our focus stays on boosting margin. Certain contracts exist that we view simply as unappealing, and we won't chase them merely to achieve volume growth and revenue growth. Therefore, my expectation is that 2025 will probably resemble a year of considerably slower expansion when it comes to membership.

Pito Chickering

analyst
#54

All right. Moving to my final question — sorry if I overlooked this earlier. Your prepared remarks mentioned a $19 million reserve tied to Brazil. Did that represent an AR write-off that hit OI? Could you walk through the specifics on it?

Joel Ackerman

executive
#55

Sure. It ran through OI during this quarter. Broadly speaking — well, not broadly, rather entirely — it related to aged AR, mostly from '23 and prior periods as well. So when I consider the international business's core earning power for 2024, this genuinely has no bearing on the underlying earning power of that business, though from an accounting perspective it did run through OI.

Pito Chickering

analyst
#56

Regarding the $491 million adjusted operating income you reported this quarter, was that figure affected by a $19 million reserve you set aside in Brazil during the same period?

Joel Ackerman

executive
#57

That's right. However, there was also a positive factor — if you're analyzing headwinds, tailwinds, earnings quality, or whatever framework you're applying, I should mention that it gained roughly $10 million from IKC revenue that was pulled forward out of 2025.

Pito Chickering

analyst
#58

Right, so that would be 491, then add 10, subtract 19 — actually add 19, subtract 10. Understood.

Joel Ackerman

executive
#59

That's a sensible way to think about it.

Javier Rodriguez

executive
#60

Alright. Michelle, thanks, and I appreciate the questions. To wrap up, let me return to the point where this call started — emphasizing 25 years of clinical innovation. We recognize the weight of our duty to carry forward DaVita's legacy, making life better for the patients we serve and the care teams who serve them. On the financial side, though the pieces behind DaVita OI and EPS growth shift annually, one thing never changes: our dedication to operational excellence and innovation; that discipline will keep being applied throughout DaVita's platform — our core dialysis metrics like revenue, cost structure and volume included — while we give excess capital back to shareholders. Thanks, everyone, for being on the call, and be well.

Operator

operator
#61

Thanks. That wraps up the conference call for today. At this point, you’re welcome to go ahead and disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete DaVita Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to DaVita Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in DaVita Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.